When added to chemotherapy, researchers found no significant difference in overall or progression-free survival between PD-1 ...

Higher calcium intake was associated with reduced colorectal cancer risk across tumor sites and calcium sources, according to ...

Susan Escudier, MD, FACP, explains some of the ways Texas Oncology mitigates financial toxicity and improve clinical trial access for underserved patients.

Panelists discuss how private label agreements facilitate biosimilar market entry by allowing manufacturers to collaborate on ...

Carrillo, MD, a postdoctoral fellow at City of Hope Comprehensive Cancer Center, discussed findings that show 76% of renal ...

Abstracts presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium reflect the ongoing ...

Investigators from Shanghai, China, report responses above 90% by using levantinib and tislelizumab to treat patients with a ...

The approach requires balance, however. There is the risk of increased AEs, as well as financial toxicity. Friedlander shared ...

In this final interview clip, Michael A. Bernstein, MD, stresses the need for effective communication and proactive screening ...

The lead investigator for EV-302 said not long ago, survival of 12 to 14 months in this type of bladder cancer was considered ...

Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody drug conjugate (ADC) combinations in advanced urothelial cancer.

Enfortumab vedotin with or without pembrolizumab offers disease control benefits for patients with upper tract urothelial cancer, said Evangelia Vlachou, MD, of Johns Hopkins Medicine.